Cleveland
Cleveland Diagnostics secures $75 million funding to advance early-stage cancer detection
Cleveland Diagnostics, a Northeast Ohio-based BioTech company, has closed a $75 million financing round to advance their early-stage cancer detection testing technology. The round was led by life sciences investment firm Novo Holdings. The funds will accelerate the commercialization of their IsoPSA blood test, an innovative technology for early detection